Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05443126 · ClinicalTrials.gov registry record · Phase 1

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

A Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Ellipses Pharma.

Recruiting
Registry status
Phase 1
Development phase
265
Enrollment target
20
Study locations

NCT05443126: Recruiting Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Ellipses Pharma.

NCT05443126 is a Phase 1 study of Advanced Solid Tumor and NSCLC that is actively recruiting participants, run by Ellipses Pharma. The registered enrollment target is 265 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05443126, a Phase 1 study of Advanced Solid Tumor and NSCLC, is actively recruiting participants, sponsored by Ellipses Pharma.

RECRUITING
Registry status
Phase 1
Development phase
265 participants
Enrollment target
20
Study locations

Study Summary

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)

Conditions Studied

Advanced Solid Tumor NSCLC

Interventions

  • DRUG EP0031

Study Locations (20)

California

  • David Geffen School of Medicine at UCLA - Los Angeles
  • Stanford University - Stanford

Illinois

  • RUSH University Medical Center - Chicago
  • Northwestern University - Evanston

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • NYU Langone Health - New York

Washington

  • Washington University - Seattle
  • Seattle Cancer Care / Fred Hutchinson Cancer Research Center - Seattle

District of Columbia

  • Georgetown University - Washington D.C.

Florida

  • Florida Cancer Specialist - Fort Myers

Kentucky

  • University of Kentucky - Lexington

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 265 participants
Start Date 2022-09-30
Est. Completion 2027-06
Phase Phase 1
Ellipses Pharma

3 total trials

What NCT05443126 shows while recruiting

NCT05443126 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (38% higher).

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which EP0031 is the first listed.

NCT05443126 names 20 study sites across 16 states, led by California, Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT05443126 about?

NCT05443126 is a clinical study titled "A Study of EP0031 in Patients With Advanced RET-altered Malignancies". The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)

What is the current status of trial NCT05443126?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 265 participants. The study started on 2022-09-30. Estimated completion is 2027-06.

What conditions does trial NCT05443126 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, NSCLC.

What interventions are being tested in trial NCT05443126?

The interventions under investigation include: EP0031 (DRUG).

Who is sponsoring clinical trial NCT05443126?

This trial is sponsored by Ellipses Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05443126 being conducted?

This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05443126's enrollment target sits among peer trials

265 41st of 189 higher than 149 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05470491 · 265 participants · Phase 1

    Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

  • NCT07301905 · 265 participants · NA

    Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI

  • NCT07470853 · 265 participants · Phase 1

    A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • NCT05098652 · 266 participants · NA

    Coaching Dementia Caregivers to Master Care-Resistant Behavior

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05443126

Source: ClinicalTrials.gov NCT05443126, the US trial registry maintained by the National Library of Medicine. NCT05443126 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.